Who makes Skin Cleanser Combination No.1?

Skin Cleanser Combination No.1 is developed by Boston Children's Hospital.

What development phase is Skin Cleanser Combination No.1 in?

Skin Cleanser Combination No.1 is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Skin Cleanser Combination No.1

Boston Children's Hospital · FDA-approved active Small molecule Quality 0/100

Skin Cleanser Combination No.1, developed by Boston Children's Hospital, is a marketed product with a key composition patent expiring in 2028. The drug's primary strength lies in its unique formulation, which differentiates it in the market. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	Skin Cleanser Combination No.1
Sponsor	Boston Children's Hospital
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Skin Cleanser Combination No.1 CI brief — competitive landscape report
Skin Cleanser Combination No.1 updates RSS · CI watch RSS
Boston Children's Hospital portfolio CI